Premium
Infarct size‐reducing effect of heat stress and α 1 adrenoceptors in rats
Author(s) -
Joyeux Marie,
GodinRibuot Diane,
Patel Asha,
Demenge Pierre,
Yellon Derek M,
Ribuot Christophe
Publication year - 1998
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0702137
Subject(s) - prazosin , medicine , endocrinology , cardioprotection , chemistry , myocardial infarction , antagonist , receptor
1 Noradrenaline (NA), which is abundantly released during heat stress (HS), is known to induce both delayed cardioprotection and heat stress protein (HSP) 72 expression by the mediation of α 1 adrenoceptors. Therefore, we have investigated the implication of α 1 adrenoceptors in HS‐induced resistance to myocardial infarction, in the isolated rat heart model. 2 Rats were pretreated with prazosin (1 mg kg −1 , i.p., Praz) or 5‐methylurapidil (3 mg kg −1 , i.v, 5MU) or chloroethylclonidine (3 mg kg −1 , i.v., CEC) or vehicle (V) in order to selectively antagonize α 1 , α 1A and α 1B adrenoceptors. They were then either heat stressed (42°C for 15 min) or sham anaesthetized. Twenty‐four hours later, their hearts were isolated, retrogradely perfused, and subjected to a 30 min occlusion of the left coronary artery followed by 120 min of reperfusion. 3 Infarct‐to‐risk ratio was significantly reduced in HS+V (15.4±1.8%) compared to Sham+V (35.7±1.3%) hearts. This effect was abolished in Praz‐treated (29.1±1.6% in HS+Praz vs 34.1±4.0% in Sham+Praz), 5MU‐treated (34.5±2.2% in HS+5MU vs 31.2±2.0% in Sham+5MU) and CEC‐treated (33.4±3.0% in HS+CEC vs 32.4±1.3% in Sham+CEC) groups. Western blot analysis of myocardial HSP72 showed an HS‐induced increase of this protein, which was not modified by Praz, 5MU and CEC pretreatments. 4 We conclude that both α 1A and α 1B adrenoceptor subtypes appear to play a role in the heat stress‐induced cardioprotection, independently of the HSP72 level. Further investigations are required to elucidate the precise role of HSPs in this adaptative response.British Journal of Pharmacology (1998) 125 , 645–650; doi: 10.1038/sj.bjp.0702137